{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=102&status=ACTIVE_NOT_RECRUITING", "query": { "status": "ACTIVE_NOT_RECRUITING", "page": 102 }, "page_size": 10 }, "pagination": { "page": 102, "page_size": 10, "total_count": 10532, "total_pages": 1054, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=103&status=ACTIVE_NOT_RECRUITING&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=101&status=ACTIVE_NOT_RECRUITING&page_size=10" }, "source": "local", "last_synced_at": "2026-11-05T23:18:52.568Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05477082", "title": "Blood Biomarkers in Pediatric Kidney Transplant Recipients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rejection of Kidney Allograft" ], "interventions": [ { "name": "Observational group", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 27, "start_date": "2023-08-21", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-05T10:14:33.456Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477082" }, { "nct_id": "NCT05455320", "title": "A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 864, "start_date": "2022-10-13", "completion_date": "2028-05-25", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-03T14:10:32.821Z", "location_count": 40, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455320" }, { "nct_id": "NCT05438043", "title": "A Study of Daratumumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 214, "start_date": "2022-12-15", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-03T20:04:34.073Z", "location_count": 7, "location_summary": "Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05438043" }, { "nct_id": "NCT05421663", "title": "A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "JNJ-90014496", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2022-08-12", "completion_date": "2041-07-30", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-04T17:17:10.826Z", "location_count": 14, "location_summary": "Duarte, California • Denver, Colorado • Iowa City, Iowa + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Piscataway", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05421663" }, { "nct_id": "NCT05388669", "title": "A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Amivantamab Intravenous", "type": "DRUG" }, { "name": "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 418, "start_date": "2022-08-05", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-04T09:22:54.692Z", "location_count": 17, "location_summary": "Duarte, California • Irvine, California • Long Beach, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388669" }, { "nct_id": "NCT05347095", "title": "A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fistulizing Crohns Disease", "Perianal Crohns Disease" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2022-09-27", "completion_date": "2027-03-25", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-04T02:34:39.447Z", "location_count": 15, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05347095" }, { "nct_id": "NCT05338775", "title": "A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/ Refractory Multiple Myeloma" ], "interventions": [ { "name": "PD-1 Inhibitor", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2022-05-25", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-03T14:10:29.713Z", "location_count": 7, "location_summary": "Denver, Colorado • New York, New York • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05338775" }, { "nct_id": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Neoplasms" ], "interventions": [ { "name": "Erdafitinib Intravesical Delivery System", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-04-11", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-05T23:18:52.568Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316155" }, { "nct_id": "NCT05306340", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Dexamethasone Mouth Rinse", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 373, "start_date": "2022-08-03", "completion_date": "2027-06-15", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-04T01:59:51.448Z", "location_count": 55, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306340" }, { "nct_id": "NCT05270525", "title": "Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive, COPD" ], "interventions": [ { "name": "Ensifentrine", "type": "DRUG" }, { "name": "LABA/LAMA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 70, "start_date": "2022-05-27", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-04T23:49:19.568Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05270525" } ] }